DalsnaFinance

AstraZeneca investors balk at prospect of $400 billion Bristol Myers pharma deal

Markets Reuters By Reuters 03 Aug 2026 16:48 1 min read
AstraZeneca investors balk at prospect of $400 billion Bristol Myers pharma deal

AstraZeneca investors balk at prospect of $400 billion Bristol Myers pharma deal  Reuters

Read the full story on Reuters → Opens the original article on news.google.com

Summary aggregated from Reuters's public RSS feed. The full reporting belongs to Reuters — please read it on their site.